Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

  • Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growth

  • Novartis secures development and commercialization rights in North America, Europe, and Japan

  • Accelerates Novartis immuno-oncology combination strategy with multiple potential tislelizumab plus Novartis therapy combinations

  • Tislelizumab already approved for patients with classical Hodgkin’s lymphoma and metastatic urothelial …
/by

Turning the sound up on patient voices in lung cancer research and development

For Pierre-Alexis Ruffié, managing clinical trials at Novartis is personal. “I don’t usually share this, but I was a cancer patient when I was younger. I had surgery and chemotherapy, so I know how it feels to be on the other side,” says Ruffié, who serves as Associate Global Trial Director in Oncology at Novartis. “You’re always wondering, ‘What are they going to find? Is it going to be worse?’ My own experience makes me pay close attention to the feelings and experiences of the people participating in our trials.”

…

/by